Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 58Active not recruiting 34Terminated 27Recruiting 24Withdrawn 10Not yet recruiting 5Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Vomiting 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × dexamethasone 21-phosphate × Clear all
NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Barbara Ann Karmanos Cancer Institute

Phase 2 Unknown
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT02576327 2016-12-30

A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation

Peking University

Phase 4 Unknown
130 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Vomiting, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡